Angiotensin (1-7) vs Ipamorelin

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

A heptapeptide formed from angiotensin II via ACE2 cleavage, or from angiotensin I via neprilysin. Acts as the endogenous counter-regulatory axis to angiotensin II — producing vasodilation, anti-fibrotic, and metabolic benefits via the Mas receptor.

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates pulsatile GH release from the anterior pituitary with high selectivity — producing minimal effect on cortisol, prolactin, or ACTH compared to earlier GHRPs. It is commonly researched for its role in supporting body composition, recovery, and lean mass maintenance.